Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.76B +117.2% |
| Revenue (ttm) | 71.78M +27.2% |
| Net Income | -295.28M |
| EPS | -3.17 |
| Shares Out | 103.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,694,888 |
| Open | 17.15 |
| Previous Close | 16.95 |
| Day's Range | 16.80 - 17.87 |
| 52-Week Range | 8.20 - 22.50 |
| Beta | 1.87 |
| Analysts | Strong Buy |
| Price Target | 31.00 (+81.93%) |
| Earnings Date | Jul 8, 2026 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical tr... [Read more]
Financial Performance
In fiscal year 2025, Nurix Therapeutics's revenue was $83.98 million, an increase of 53.95% compared to the previous year's $54.55 million. Losses were -$264.46 million, 36.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $31.0, which is an increase of 81.93% from the latest price.
News
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median prog...
Nurix Therapeutics price target raised to $32 from $30 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $30 and keeps a Buy rating on the shares. The company’s disclosed partnership with…
Nurix Therapeutics price target raised to $32 from $30 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $30 and keeps a Buy rating on the shares. The firm notes that the…
Nurix Therapeutics price target raised to $32 from $30 at Truist
Truist raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $30 and keeps a Buy rating on the shares. The firm views this morning’s disclosed partnership with…
Nurix Therapeutics price target raised to $45 from $41 at Jefferies
Jefferies analyst Roger Song raised the firm’s price target on Nurix Therapeutics (NRIX) to $45 from $41 and keeps a Buy rating on the shares after the company announced a…
Nurix Therapeutics price target raised to $34 from $26 at Needham
Needham raised the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $26 and keeps a Buy rating on the shares after the company announced a strategic collaboration with…
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal
As previously reported, Wells Fargo downgraded Nurix Therapeutics (NRIX) to Equal Weight from Overweight with a price target of $25, down from $28. While the economics of the deal with…
Nurix Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Nurix Therapeutics (NRIX) to Equal Weight from Overweight with a $25 price target
Nurix Therapeutics Transcript: Study update
A major global partnership was announced to co-develop and commercialize Bexdeg, a BTK degrader, across oncology, immunology, and neurology. Robust clinical data, a broad development plan, and a $2.3B deal structure position Bexdeg as a potential backbone therapy for BTK-driven diseases.
Nurix Therapeutics Press release: Study update
Nurix Therapeutics issued a press release on June 8, 2026, disclosing material business information to investors.
Nurix Therapeutics Slides: Study update
Nurix Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche
Shares in biopharmaceutical company Nurix Therapeutics ($NRIX) soared nearly 40% in pre-market trading after sealing a $2.3 billion blood cancer deal with Swiss pharmaceutical giant Roche ($RHHBY). Bl...
Nurix Therapeutics teams with Roche to develop, commercialize bexobrutideg
Nurix Therapeutics (NRIX) announced a global collaboration with Roche (RHHBY) to develop and commercialize bexobrutideg, an oral degrader of Bruton’s tyrosine kinase, or BTK. The partnership brings to...
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica...
Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Upcoming data at EHA will highlight strong response rates for the BTK degrader in CLL, with pivotal trials and combination studies launching mid-year. Partnerships and a robust pipeline, including autoimmune and immuno-oncology programs, support a multi-indication strategy.
Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
BTK degraders demonstrate high efficacy and durability in CLL, with bexobrutideg showing best-in-class potential and advancing through pivotal trials. Expansion into autoimmune and neurology indications is underway, supported by strong preclinical and early clinical data. Partnerships with Gilead and Sanofi further diversify the pipeline.
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteer...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther...
Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Lead BTK degrader is advancing to phase III for CLL, showing strong efficacy and safety, with a new confirmatory trial against pirtobrutinib. Autoimmune and early-stage programs are progressing, and the company is well-funded with $650M in cash.